Prevalence of comorbidities and use of medication in psoriatic arthritis patients: findings from a Mexican cohort

Abstract

Introduction

Comorbidities contribute to the development of PsA and worsen disease severity. The aim of the study is to describe the clinical characteristics of Mexican PsA patients focusing on comorbidities and medications. The primary objective of our study was to investigate the clinical and epidemiological characteristics of patients with Psoriatic Arthritis (APs) who were undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs).

Materials and methods

We conducted a cross-sectional observational study in a secondary care clinic in northern Mexico.

Results

Of the total sample, 38/66 (57.5%) were women, with a mean age of 47.8 (SD 11.5) years, a mean weight of 83.8 (SD 19) kg, and BMI of 31.5 (SD 6.5) kg/m2. Smoking and alcoholism were reported in 10/66 (15.1%) and 2 (3%) of patients, respectively.

Obesity occurred in 41 (62.1%) patients, followed by diabetes mellitus in 23 (34.8%) patients, and systemic arterial hypertension in 19 (28.7%) patients. Ischaemic heart disease, heart failure, and cancer were not present in any of the patients.

Conclusions

0ur study revealed a higher prevalence of chronic metabolic diseases among patients with psoriatic arthritis (PsA) compared to other cohorts without inflammatory arthropathy and the Mexican population.